Upper Tract Urothelial Carcinoma
Advertisement
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Dr. Moussa provides an overview of his research on prognostic factors of relapse in small cell neuroendocrine carcinomas.
The use of minimally invasive RNU is linked to improved median OS and 90-day mortality in octogenarian patients with UTUC.
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Dr. Lerner shares updates from the ENLIGHTED trial and analyses pertaining to NAC for UTUC from the ROBUUST registry.
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Padeliporfin VTP has previously shown positive safety and efficacy results for patients with low-grade UTUC.
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
The only guideline-recommended endoluminal treatment option for patients with HG UTUC is bacillus Calmette-Guérin.
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
The nomogram is used preoperatively to determine the probability of nodal tropism.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.